The figure quality concerns raised during peer review also apply more broadly: future publications in this space would benefit substantially from high-resolution conceptual frameworks that clearly depict the relationships between formulation platform, pharmacokinetic exposure, patient phenotype, and clinical outcomes
The translation for the food industry would be how things are packaged and presented to a person perhaps. Supplements or nutrient-dense foods that tackle the secondary impact of reduced calories on micro and macronutrient intake is another potential area of opportunity, believes Jana Abelovska, superintendent pharmacist at Click Pharmacy
None of these replace a prescription, and if youre managing a condition like type 2 diabetes or obesity, you need to see a healthcare provider before making major dietary changes
Start your online mental health evaluation with Nurx today
Eli Lilly (NYSE: LLY) saw its shares climb 5% this past week after announcing that its history-making oral obesity candidate, orforglipron aced the Phase III ATTAIN-2 trial (NCT05872620), which assessed the small molecule glucagon-like peptide-1 (GLP-1) receptor agonist in adults who were obese or overweight and had type 2 diabetes
